Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2019-02-25 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 25 pages 1.3MB
Regulatory Filings
2019-02-25 English
Half Year Report & DMX-200 Clinical Trials Update 2 pages 191.3KB
Regulatory Filings
2019-02-25 English
Appendix 4C and Quarterly Highlights 5 pages 267.5KB
Regulatory Filings
2019-01-30 English
Appendix 3B 12 pages 394.9KB
Regulatory Filings
2019-01-28 English
Appendix 3B 12 pages 395.7KB
Regulatory Filings
2019-01-13 English
Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m 1
Regulatory Filings
2018-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.